Rescue Heat

**Product and the concrete problem it solves.** Rescue Heat is a smart, adhesive thermal patch built to prevent and reverse hypothermia in trauma casualties — a leading but under-appreciated killer on the battlefield and in civilian trauma alike. Hypothermia is one leg of trauma's lethal triad (with acidosis and coagulopathy): once a bleeding patient's core temperature falls below roughly 35 degrees Celsius (95 degrees Fahrenheit), blood clotting deteriorates, bleeding worsens, and mortality rises sharply — even in temperate conditions — because hemorrhage, shock-driven peripheral vasoconstriction, and environmental exposure strip heat from the body faster than a wounded person can replace it. Existing field options — mylar space blankets, insulated wraps, and short-lived chemical warmers — mostly retain heat passively or run hot for only a brief window. Rescue Heat, developed by the Israeli biomedical-engineering firm Noyad Biomed in partnership with Rambam Health Care Campus, is instead an active rewarming device: a thin sticker applied directly to the casualty's skin that delivers controlled heat during the critical minutes-to-hours of point-of-injury care and evacuation to a trauma center.

**Core technology and how it actually works.** The patch is an air-activated exothermic device: according to its developers and Rambam Health Care Campus, it springs into action when shaken and exposed to air, reaching about 42 degrees Celsius (107.6 degrees Fahrenheit) within roughly 15 minutes and holding that temperature for up to eight hours — a large improvement over incumbent field warmers that developers say sustain useful heat for 90 minutes or less, with a claimed order-of-magnitude (tenfold) gain in heat transfer to the patient. Two engineering choices matter most: (1) a temperature ceiling engineered as a skin-safety limit, so the patch actively warms without causing contact burns and can be applied directly to injured skin; and (2) a thin, light, adhesive form factor that fits a medic's existing kit and can be applied quickly under field conditions. Noyad reports bench research comparing the patch against five active heating technologies and five passive heat-retention methods, in which it demonstrated superior efficiency.

**Market, customers, and go-to-market.** Rescue Heat's initial customer is the military medical channel: the developers state their goal is for the patch to become standard-issue casualty-care equipment for the IDF, U.S. forces, and other militaries. That market is governed by combat-casualty-care doctrine — the U.S. TCCC/MARCH protocol and equivalent NATO guidance explicitly include preventing hypothermia as a core step — and by the logistics of the hypothermia-prevention-and-management kits (HPMKs) that medics already carry, so adoption depends on fitting existing doctrine, kit, and procurement cycles rather than creating a category from scratch. Beyond the military, the same physiology drives demand across civilian pre-hospital care: ambulance and EMS trauma response in cold weather, wilderness and mountain rescue, maritime search-and-rescue, and mass-casualty disaster response. Go-to-market is therefore twofold — defense procurement seeded by early IDF field use, and a broader civilian medical-device path that hinges on regulatory clearance (FDA/CE) and distribution partnerships that are not yet publicly disclosed.

**Traction, funding, and third-party validation.** The strongest validation is real-world use: multiple reputable Israeli outlets and Rambam itself report that initial patches have been delivered to, and are being tested by, selected elite IDF units in combat in Gaza (and, per ISRAEL21c reporting, Lebanon) — unusually direct field evidence for such an early product. Development has been conducted in partnership with Rambam Health Care Campus in Haifa, whose Dr. Amit Lehavi co-developed the device, an academic-medical validation signal. Reported status is calibrated-early: the patch has passed feasibility testing in the laboratory and on healthy human skin, the heating material is described as patent-registered or patent-pending, and the product is reported to be pursuing U.S. FDA approval, which it has not yet obtained. Critically, no institutional venture round, revenue figure, headcount, or contract value has been publicly disclosed; this appears to be an in-house venture of Noyad Biomed rather than a separately VC-financed startup, and those commercial facts should be treated as Unknown pending direct diligence.

**Founders and team background.** Rescue Heat is developed by Noyad Biomed, a boutique medical-device R&D engineering firm based at Kibbutz Lavi in northern Israel (founded 2013) that describes itself as a turn-key partner taking devices from concept to FDA approval. Its CEO, Hagay Weisbrod, holds a B.Sc. in biomedical engineering from the Technion and is a reserve paratrooper battalion commander in the IDF — a rare combination of device-engineering depth and firsthand operational understanding of casualty care under fire, which plausibly explains the product's field-first design. The clinical anchor is Dr. Amit Lehavi, director of the pediatric anesthesia unit at Rambam and a military physician with disaster-rescue experience, who serves as medical advisor and co-developer; Adi Shalev is cited managing the Rescue Heat project and operations, with additional scientific advisory support named in company profiles. The team's strength is domain fit and clinical credibility; its limitation is that it is small and rooted in a services-oriented R&D house rather than a scaled product company.

**Competitive dynamics.** Rescue Heat competes against entrenched, low-cost incumbents in military and civilian hypothermia management. (1) Self-heating blankets — most notably TechTrade's Ready-Heat and the North American Rescue Hypothermia Prevention & Management Kit (HPMK) with its Heat Reflective Shell — are already fielded at scale by U.S. and allied militaries and set the procurement benchmark. (2) Reflective heat-retention systems such as Blizzard Survival's Reflexcell blankets and bags are widely used by NATO forces for passive insulation. (3) Cheap, ubiquitous options — mylar emergency blankets and air-activated chemical hand and body warmers (for example HotHands-type iron-oxidation warmers) — are the improvised status quo. (4) In definitive care, forced-air warming systems like the 3M Bair Hugger dominate hospitals but are not field-portable. Rescue Heat's differentiation is a genuinely long active-warming window (up to roughly eight hours) at a safe, controlled skin temperature in a thin adhesive form — attacking the gap between short-lived active warmers and passive-only insulation. Its vulnerabilities are incumbency, price, and unproven at-scale manufacturing.

**Defense, security, and resilience dual-use relevance.** This is a genuinely core dual-use technology rather than an adjacency. The identical device serves (1) military casualty care — keeping wounded soldiers alive during prolonged field care and evacuation, directly supporting TCCC/MARCH hypothermia-prevention doctrine — and (2) civilian resilience — EMS trauma, wilderness and maritime rescue, and mass-casualty disaster response, where cold-induced coagulopathy kills the same way. Hypothermia prevention is a recognized force-health-protection and combat-effectiveness issue, and casualty-survivability improvements carry strategic value for any military and for national emergency-preparedness systems. The dual-use credibility here is unusually strong because the device is already being used in an active combat theater rather than merely proposed for one. The honest calibration: its strategic weight sits at the individual-casualty and logistics level rather than the platform or systems level — it is a resilience-and-survivability enabler, clearly and materially dual-use, but modest in scale relative to sensing, autonomy, or infrastructure plays.

**Growth stage, trajectory, and key diligence risks.** Rescue Heat is early-stage: a first-generation, largely single-product device with combat feasibility use but pre-regulatory-clearance status and no disclosed institutional funding, revenue, or scaled manufacturing. Its trajectory — from Rambam-partnered R&D and IDF field trials toward standard-issue military kit and, later, civilian medical-device sales — is plausible and well-timed given wartime demand, but the execution risk is real. Key diligence risks: (1) regulatory — the device is not FDA-cleared and CE status is unclear, so timeline and outcome are uncertain; (2) single-product concentration inside a small, services-rooted firm with limited disclosed dedicated capital; (3) procurement — military medical adoption is slow and doctrine/kit-driven, and civilian EMS uptake is uncertain; (4) manufacturing, shelf-life, and quality at volume for a skin-contact exothermic product across climates; (5) IP breadth — a patent is claimed on the heating material, but its defensibility versus established warmer chemistry is unverified; and (6) clinical evidence — efficacy rests on bench and feasibility data plus early field use, without published peer-reviewed trauma-outcome trials. The bull case is a clinically credible, combat-validated survivability product with a clear dual-use market; the bear case is a small firm facing regulatory, capital, and procurement hurdles against cheap incumbents.